A first-in-human feasibility trial of SpyGlass Pharma’s drug-delivery platform demonstrated a 45% drop in mean IOP at 3 months, according to a news release. The platform consists of a single-piece, hydrophobic acrylic IOL with drug-eluting pads attached to the haptics. It is implanted into the capsular bag during cataract surgery and designed to deliver multiple years of bimatoprost to lower IOP in patients with glaucoma or ocular hypertension.